3072 Phase 2: Docetaxel with or without ramucirumab as...

European Journal of Cancer 2015 / 09 Vol. 51

3072 Phase 2: Docetaxel with or without ramucirumab as therapy for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations after prior EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy

Kasahara, K., Kiura, K., Nogami, N., Takayama, K., Takiguchi, Y., Hirashima, T., Aoe, K., Hayashi, H., Saka, H., Takahashi, K., Imamura, F., Oizumi, S., Inoue, A., Satouchi, M., Tatsumi, M., Nakamura,
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
51
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/s0959-8049(16)31713-0
Date:
September, 2015
File:
PDF, 59 KB
english, 2015
Conversion to is in progress
Conversion to is failed